FindTrial
Sign In

Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Efficacy of Evolocumab in patients with arteriosclerosis obliterans. - Efficacy of Evolocumab in patients with arteriosclerosis obliterans.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032844
Enrollment
20
Registered
2018-06-02
Start date
2018-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis obliterans

Interventions

evolocumab140mg/2weeks for 48 weeks

Sponsors

Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with arteriosclerosis obliterans having -Dyslipidemia undergoing treatment with HMG-CoA reductase inhibition -LDL-C 100 mg/dL or more in conventional therapy

Exclusion criteria

Exclusion criteria: -HMG-CoA reductase inhibitor is not used at the time of introduction -At the time of introduction of research drugs, patients with LDL-C less than 100 mg / dL -Contraindicated patients with HMG-CoA reductase inhibitors -Hypersensitivity to the study drug

Design outcomes

Primary

MeasureTime frame
the ratio of lower limb amputation after 48 weels—

Countries

Japan

Contacts

Public ContactHiroyasu Uzui

Faculty of Medical Sciences, University of Fukui Department of Cardiovascular Medicine

huzui@u-fukui.ac.jp0776-61-8800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026